Beactica is a drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platformand services in the area of SPR biosensor-based interaction analysis.

Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery.

Latest News


Upcoming events

11-14 January, 2016, Beactica holds meetings in conjunction with the 34rd Annual JP Morgan Healthcare Conference in San Francisco, USA.